YumanityLogo.jpg
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
November 16, 2021 16:30 ET | Yumanity Therapeutics Inc
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 15, 2021 07:30 ET | Yumanity Therapeutics Inc
Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles Company...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2021 16:05 ET | Yumanity Therapeutics Inc
BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2
November 10, 2021 07:00 ET | Yumanity Therapeutics Inc
YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson’s disease YTX-7739 found to be generally well tolerated, demonstrating favorable...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 14, 2021 07:00 ET | Yumanity Therapeutics Inc
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2021 16:15 ET | Yumanity Therapeutics Inc
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference
September 09, 2021 08:00 ET | Yumanity Therapeutics Inc
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
August 16, 2021 07:00 ET | Yumanity Therapeutics Inc
BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
August 12, 2021 16:15 ET | Yumanity Therapeutics Inc
YTX-7739 shown to inhibit its novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease Topline results for the YTX-7739 Phase 1b...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 06, 2021 07:00 ET | Yumanity Therapeutics Inc
BOSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...